In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

Overall, 35% of patients' records had evidence of comprehensive genomic profiling (CGP). The rate increased modestly from 32% at the beginning of the study period to 39% at the end, reported Stacey ...

NMDPSM, a global nonprofit leader in cell therapy, and its collaborative research program, CIBMTR (Center for International ...

The agency disclosed a tranche of more than 200 complete response letters from the past five years, but only those involving ...